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Summary 
Ivermectin is being considered for mass-drug-administration for malaria due to its ability to 
kill mosquitoes feeding on recently treated individuals. Membrane-feeding, which is more 
patient-friendly, likely reliably reflects the effects of direct-skin-feeding in assessing 
ivermectin’s mosquitocidal-efficacy.
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Abstract 
Background 
Ivermectin is being considered for mass-drug-administration for malaria due to its ability to 
kill mosquitoes feeding on recently treated individuals. In a recent trial, 3-day courses of 300 
and 600 mcg/kg/day were shown to kill Anopheles mosquitoes for at least 28 days post-
treatment when fed patients’ venous blood using membrane-feeding-assays. Direct-skin-
feeding on humans may lead to higher mosquito-mortality as ivermectin capillary-
concentrations are higher. We compared mosquito-mortality following direct-skin- and 
membrane-feeding. 
Methods 
We conducted a mosquito feeding study nested within a randomized, double-blind, 
placebo-controlled trial of 141 adults with uncomplicated malaria in Kenya comparing 3-day 
ivermectin 0 (n=46), 300 (n=48), or 600 mcg/kg/day (n=47), co-administered with 
dihydroartemisinin-piperaquine. On post-treatment day-7, direct-skin and membrane-
feeding assays were conducted using laboratory-reared Anopheles gambiae s.s.. Mosquito 
survival was assessed daily for 28-days-post-feeding.  
Results 
Between July-20-2015 and May-7-2016, 69 of 141 patients participated in both direct-skin- 
and membrane-feeding (placebo n=23, 300mcg/kg/day n=24, 600mcg/kg/day n=22). The 
14-day-post-feeding mortality for mosquitoes fed on blood 7-days post-treatment from 
patients in both ivermectin arms pooled was similar with direct-skin-feeding (n=2,941 
mosquitoes) versus membrane-feeding (n=7,380 mosquitoes): cumulative-mortality 
(RR=0.99, 0.95-1.03, p=0.69) and survival-time (HR=0.96, 0.91-1.02, p=0.19). Results were 
consistent by sex, body-mass-index, and across the range of ivermectin capillary 
concentrations studied (0.72-73.9 ng/mL). 
Conclusions 
Direct-skin-feeding and membrane-feeding on day 7 resulted in similar mosquitocidal-
effects of ivermectin across a wide range of drug-concentrations, suggesting that the 
mosquitocidal-effects seen with membrane-feeding accurately reflect those of natural-
biting. Membrane-feeding, which is more patient-friendly and ethically acceptable, can 
likely reliably be used to assess ivermectin’s mosquitocidal-efficacy. 
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Trial registration:ClinicalTrials.gov-NCT02511353. 
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Background 
Mass drug administration (MDA) for malaria is the treatment of the entire eligible 
population in an endemic area, regardless of individuals’ infection status or whether they 
have symptoms, and is currently being evaluated in several countries to accelerate progress 
towards malaria transmission reduction and elimination [1-3] . The antimalarial 
dihydroartemisinin-piperaquine (DP) is most commonly used for MDA because of its slow 
elimination providing 4-6 weeks of post-treatment prophylaxis against new infections. 
Ivermectin is an antiparasitic drug, which also kills mosquitoes feeding on recently treated 
individuals. Adding ivermectin to DP has been proposed as an innovative tool to increase 
the impact of MDA for malaria by killing mosquitoes before they become infective 10-14 
days after ingesting malaria parasites, and by reducing overall mosquito numbers in the 
community [4-6]. However, the single-dose of 150-200 mcg/kg ivermectin used for 
onchocerciasis and lymphatic filariasis control has only a small and short-lived effect (<7 
days) on mosquito mortality [5]. Ivermectin is documented to be remarkably well tolerated, 
even up to doses of 2,000 mcg/kg [7, 8]. 
In a recent trial, high-dose, 3-day courses of ivermectin 300 and 600 mcg/kg/day, co-
administered with DP, were shown to kill Anopheles mosquitoes for at least 28 days post-
treatment when fed patients’ venous blood using membrane feeding assays [6]. Membrane 
feeding assays may however underestimate the mosquitocidal effect of ivermectin in 
comparison to direct skin feeding where mosquitoes bite the human subject directly, due to 
potential differences in ivermectin concentrations between venous blood (used in 
membrane feeding) and blood in subdermal venules and arterioles (the main source of 
blood for mosquitoes during direct skin feeding). Ivermectin is known to accumulate in 
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subcutaneous fat, dermal, and fascial tissue at 2-3-fold higher concentrations than in venous 
blood [9]. In the recent trial, ivermectin concentrations were 1.33 fold higher in capillary 
versus venous blood [10]. 
 Ivermectin feeding studies with direct skin feeding on a human [11], and cattle [12], 
have shown a longer mosquitocidal effect (>2 weeks) in comparison with other studies using 
membrane feeding (<7 days) [13]. A single study, including 6 human subjects, compared 
direct and membrane feeding 4 hours after a single-dose of ivermectin 200 mcg/kg and 
found that mortality was higher after direct skin feeding (HR=1.73, 95% CI 1.57-1.90, 
p=0.0001) [14]. Any difference between feeding methods could have important implications 
for both pharmacokinetic-pharmacodynamic [10] and population-level [15] models 
assessing the impact of ivermectin on mosquito mortality and through mass drug 
administration on malaria transmission. To date these models have relied on membrane 
feeding estimates of ivermectin’s mosquitocidal efficacy. 
We directly compared mosquito mortality following direct skin feeding versus 
membrane feeding in our trial on 3-day ivermectin courses of 300 and 600 mcg/kg/day. 
 
Methods 
Trial Design 
Details of the trial design, procedures, and safety, efficacy and pharmacokinetic-
pharmacodynamic (PK-PD) results have been published elsewhere [5, 6, 10]. Briefly, the 
study was a randomized, double-blind, placebo-controlled, parallel 3-arm, superiority trial 
(ClinicalTrials.gov: NCT02511353). Adults with uncomplicated P. falciparum malaria in 
western Kenya (n=141) were randomly assigned (1:1:1), stratified by sex and body-mass 
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index, to receive 3 days of ivermectin 600 mcg/kg/day (n=47), 300 mcg/kg/day (n=48), or 
placebo (n=46), all co-administered with 3 days of dihydroartemisinin-piperaquine. The 
primary methodology used membrane feeding to assess the mosquitocidal efficacy of 
ivermectin. On day 7, the current nested sub-study compared direct skin feeding versus 
membrane feeding. 
 
Patients 
All patients enrolled in the main trial were eligible to participate in the current sub-study 
provided they gave additional written consent for direct skin feeding [5]. Up until day 7 
when direct skin feeding took place, participants were given the opportunity to ask 
questions, familiarize themselves with the procedures in the lab, make their decision and/or 
change their minds. Participation or refusal to participate in the direct skin feeding sub-
study did not affect patients’ participation in the main trial or their malaria treatment. After 
direct skin feeding, patients were provided a tube of hydrocortisone cream to take home to 
reduce possible itching. 
 
Membrane Feeding Procedure 
In accordance with a standard membrane feeding protocol [16], a 1 mL sample of the 
participant’s venous blood was drawn into a sodium-heparin coated tube pre-heated to 
37.5° C. Within 2 minutes the blood was placed in a water-jacketed glass-bell parafilm 
membrane feeding system heated to 37.5° C and 3 cups of mosquitoes commenced feeding 
for 20 minutes. Follow-up lasted 28 days for mosquito survival (2 cups) and 10 days for 
oocyst prevalence (1 cup).  
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy1063/5257992 by U
niversity of Liverpool user on 02 January 2019
 Page 7 of 24 
Direct Skin Feeding Procedure 
Immediately after the blood draw for membrane feeding, and in accordance with previous 
direct skin feeding studies examining infectivity [17], one cup of mosquitoes was placed 
directly on the skin of the participant and allowed to feed for 15 minutes. Follow-up lasted 
28 days for mosquito survival. 
 
General Insectary Procedures 
For both methods, each feeding used new cups of 50, 3 to 5-day old female, insectary-
reared, infection-free An. gambiae s.s. Kisumu strain mosquitoes. Post-feeding, the number 
of mosquitoes with an engorged abdomen (fully fed) were counted and those with lean 
abdomens (semi- and unfed) discarded. Each day the number of dead mosquitoes were 
counted and removed until the end of the follow-up period (see feeding procedures above). 
After the initial feeding on human blood, the mosquitoes were kept in a temperature and 
humidity-controlled insectary (27° C, 80%), with fixed light-dark cycle (12h/12h) and 
maintained ad libitum on 10% sugar feeds. Insectary staff assessing mosquito survival were 
blinded to all characteristics of the cups, including: participant identification, study arm, 
duration between treatment and feeding, and feeding method. 
 
Outcome Measures  
The primary outcome was cumulative mosquito mortality 14 days after feeding (henceforth 
referred to as post-feeding) on blood taken from patients who started the 3-day ivermectin 
and dihydroartemisinin-piperaquine regimen 7 days earlier (henceforth referred to as post-
treatment). The secondary outcome was the daily survival of mosquitoes up to day 14 post-
feeding. Paired venous and capillary ivermectin plasma concentrations were collected on 
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post-treatment days 2-7; The predicted concentrations on day 7 were obtained from our 
previously published PK-PD analysis [10]. 
 
Statistical Analysis 
The analysis was based on the intention-to-treat (ITT) population. Only mosquito and 
pharmacokinetic data from participants that contributed to both direct and membrane 
feeding was included. Mosquito mortality was assessed for fully fed mosquitoes. Cumulative 
mosquito mortality was analyzed using the Generalized Estimating Equations (GEE) model, 
with a binomial distribution, log link function, the feeding method (direct or membrane) as 
the only predictor, and taking the cluster design into account. Risk ratios (RR) and their 95% 
confidence intervals were derived from the GEE model. Survival time of mosquitoes post-
feeding was analyzed using Cox-regression with feeding method as the only predictor, 
adjusted for mosquito clusters (using shared frailty with γ distribution) to derive hazard 
ratios (HR). For GEE models, analysis was based on data collected for approximately 100 
mosquitoes (2 cups of 50) per participant for membrane feeding and 50 mosquitoes (1 cup 
of 50) per participant for direct skin feeding. Additional membrane fed mosquitoes used for 
oocyst PCR (1 cup of 50) were excluded from the GEE analyses on day 14 as they had all 
been euthanized after 10 days of mosquito follow-up. For Cox models, analysis was based 
on data collected from approximately 150 mosquitoes (3 cups of 50) per participant for 
membrane feeding and 50 mosquitoes (1 cup of 50) per participant for direct skin feeding. 
This included the membrane fed mosquitoes used for oocyst PCR (1 cup of 50) which were 
euthanized after 10 days, and therefore contributed a maximum of 10 days of survival data. 
The above analyses were performed separately by treatment arm and pooled across the 
two ivermectin arms. Pearson’s correlation coefficients (ρ) were determined for mosquito 
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mortality rate ratios (direct versus membrane feeding) and ivermectin concentrations 
(capillary-venous ratios), and were stratified by known determinants of ivermectin 
pharmacokinetics (sex and body-mass-index) [10]. Analyses were performed using Stata 
v14.2. 
 
Ethics 
All patients gave written informed consent to participate in the main trial and additional 
written informed consent to participate in direct skin feeding on day 7 post-treatment. The 
study was approved by the ethics committees of participating institutions [5]. 
 
Results 
Between July 20th, 2015 and May 7th, 2016, 141 patients were randomized to ivermectin 600 
mcg/kg/day (n=47), 300 mcg/kg/day (n=48), or placebo (n=46). 128 patients (90.8%) 
attended the primary outcome visit 7 days post-treatment, of which 69 patients (54%) 
participated in both direct and membrane feeding: ivermectin 600 mcg/kg/day (n=22), 300 
mcg/kg/day (n=24), or placebo (n=23) (Figure 1 and Table 1). 
 The proportion of mosquitoes that fully fed was higher for direct skin feeding 
(2,941/3,446; 85.3%) versus membrane feeding (7,380/10,368; 71.2%) (RR 1.20, 95% CI 
1.12-1.28, p<0.0001), however this did not differ by treatment arm for either method (Table 
2). 
Compared with membrane feeding, direct skin feeding was associated with similar 
14-day post-feeding mosquito mortality when fed on blood 7 days post-treatment, both in 
terms of cumulative mortality (ivermectin 600 mcg/kg/day risk ratio [RR] 0.98, 95% CI 0.90-
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1.06, p=0.55; ivermectin 300 mcg/kg/day RR 1.01, 0.98-1.03, p=0.69; placebo RR 1.07, 0.88-
1.29, p=0.51) and survival time (ivermectin 600 mcg/kg/day hazard ratio [HR] 0.93, 0.86-
1.00, p=0.05; ivermectin 300 mcg/kg/day HR 1.01, 0.93-1.09, p=0.80; placebo HR 1.03, 0.92-
1.15, p=0.58) (Figure 2 and Table 3). Similar results were seen upon pooling the two 
ivermectin arms (HR 0.96, 0.91-1.02, p=0.19; RR 0.99, 0.95-1.03, p=0.69). 
 Based on the previously published trial’s population PK-PD model [10], the predicted 
median (percentiles 5th-95th [p5-p95]) ivermectin concentrations in venous blood at day 7 
were 17.3 (2.87-43.0), 7.75 (1.58-18.7), and 11.3 (1.58-39.5) ng/mL for the ivermectin 600 
mcg/kg/day, 300 mcg/kg/day, and combined arms respectively. The corresponding 
predicted capillary blood concentrations were 24.2 (6.04-58.6), 8.22 (1.54-22.6), and 14.3 
(p5-p95: 1.60-49.4; min-max: 0.72-73.9) ng/mL. The capillary-venous ratio of the observed 
ivermectin plasma concentrations remained consistent from day 2+4h through day 7 near 
the population predicted median ratio of 1.33 (Figure 3) [10]. 
 The median (p5-p95) mosquito mortality rates (deaths/100 days) per sample for 
each feeding method (both ivermectin arms pooled) at day 7 of the study were 24.1 (6.96-
50.0) for direct skin feeding and 24.0 (6.73-48.3) for membrane feeding. The ratio of direct 
versus membrane feeding mosquito mortality rates was not affected by patients’ ivermectin 
plasma concentrations or capillary-venous ratios within the ranges studied, overall and 
when stratified by sex and body mass index (BMI) (Figure 4). 
 
Discussion 
Direct skin feeding and membrane feeding conducted at day 7 post-treatment resulted in 
similar mosquitocidal effects of ivermectin. This was seen in each of the 300 and 600 
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mcg/kg/day treatment arms and when combined, was not dependent on patients’ 
ivermectin plasma concentrations or capillary-venous ratio and was seen irrespective of 
whether mortality was assessed as a proportion or a rate. Membrane feeding, which is more 
patient-friendly, can likely reliably be used to assess ivermectin’s mosquitocidal effects.  
 Although mosquito mortality was only assessed at a single timepoint post-treatment 
on day 7, results may be applicable to earlier or later feeding time points. This is because 
the lack of difference in mosquito mortality between the two feeding methods was 
observed across the full range of ivermectin capillary concentrations tested (min-max: 0.72-
73.9 ng/mL) (Figure 4), with corresponding mosquito mortality rates (direct skin feeding: 
median: 24.1, p5-p95: 6.96-50.0; membrane feeding: median: 24.0, p5-p95: 6.73-48.3) 
covering nearly the entire mosquitocidal effect range found in the main trial (E50: 28.7; Emin-
Emax: 3.9-53.4) [10]. Although differences between direct and membrane feeding were not 
assessed for capillary concentrations above 73.9 ng/mL, mosquito mortality by day 14 at 
these concentrations (incidence rate ratio >10.6) is near universal, making it unlikely that 
clinically meaningful differences would exist between feeding approaches. Although it is 
possible that a differential effect between direct and membrane feeding is only evident at 
lower concentrations when the mosquitocidal effect is low, this is not suggested by our 
analysis that shows a similar lack of difference between the two feeding methods even at 
the lowest concentrations studied. 
It is unclear why the higher concentration of ivermectin in capillary blood compared 
to venous blood, a capillary-venous plasma ratio of 1.33 that was consistent across the 
range of blood concentrations tested in the main trial (Figure 3) [10], does not translate to 
higher mosquito mortality in direct skin feeding. The surface area available for feeding was 
larger for direct feeding (8 cm diameter of the cup exposed to the skin vs. 1.8 cm diameter 
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of the artificial membrane), possibly leading to less crowding and explaining the higher 
proportion of fully fed mosquitoes in direct skin feeding. If capillary blood samples reflect 
the blood source of skin-fed mosquitoes and the concentration of ivermectin imbibed, 
counterbalancing forces must be at play. One possible explanation is that direct skin fed 
mosquitoes consumed a smaller blood volume than membrane fed mosquitoes, despite all 
analyzed mosquitoes visually appearing to be fully fed. This was suggested in a previous 
study with Anopheles aquasalis, a Latin American malaria vector, that found a 48% 
difference in mean post-feeding weight between direct skin fed (0.040 mg, SD=0.02) and 
membrane fed mosquitoes (0.059, SD=0.02) [14]. Such a difference in blood meal size may 
reflect differences in the blood flow between the two procedures or the energy involved in 
taking a blood meal, both of which might favor a larger blood meal in membrane feeding. 
Future, studies could assess blood meal volumes following direct and membrane feeding, 
for example by measuring hemoglobin in fed mosquitoes. Furthermore, it is not clear if 
other factors associated with skin feeding that are not present in the membrane feeds (e.g. 
dermal immune mechanisms) could reduce ivermectin’s mosquitocidal effect with direct 
skin feeding. 
Only one previous study has directly compared direct versus membrane feeding [14]. 
This small study in six human subjects in Brazil used feeding assays conducted 4 hours after 
a single-dose of 200 mcg/kg (i.e. Tmax) and reported significantly higher mortality of the Latin 
American malaria vector An. aquasalis following direct skin feeding [14]. A single-dose of 
ivermectin 200 mcg/kg has a predicted plasma Cmax (median, p5-p95) of 27 ng/mL (18.8-
41.4) [5], which is within the 1.58-39.5 ng/mL range of the venous plasma concentrations 
tested in our current study. The hazard ratio following membrane feeding at 4h after this 
single 200 mcg/kg dose was 3.2, which is not that different from the 4.4 in the 300 
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mcg/kg/day arm in our study. It is not clear whether the differences between the two 
studies can be explained by differences in pharmacodynamic factors (i.e. ivermectin 
sensitivity of the Anopheles species), pharmacokinetic factors due to differences in study 
populations (i.e. ethnic group and clinical indication; Kenyan patients with acute 
uncomplicated malaria versus Brazilian patients with other indications for ivermectin 
treatment), or differences in the timing of feeding post-treatment (i.e. 7 days versus 4 hours 
after ingestion). It is also possible that the higher mosquito mortality observed with direct 
skin feeding in the Brazilian study reflects a chance finding given the small numbers of 
subjects (n=6). 
As the relationship between ivermectin concentration, both venous and capillary, 
and mosquitocidal effect has been previously established for membrane feeding [10], and 
the current study shows no difference in mosquitocidal efficacy between direct skin and 
membrane feeding, future studies could consider using ivermectin concentration in either 
venous blood or in capillary blood obtained from finger-prick samples as a proxy of the 
potential mosquitocidal effect, without the need to invoke more labor intensive and 
patient-unfriendly membrane or direct skin feeding assays. The similarity in mosquitocidal 
efficacy between feeding methods also has important implications for population-level 
models used to predict the impact of ivermectin mass drug administration on malaria 
transmission [15]. Due to the sparse availability of direct skin feeding data, these models 
have relied on mosquitocidal efficacy estimates from membrane feeding, using either spiked 
blood [12, 13, 18, 19] or blood samples from humans [13]. Our results, which show that 
membrane feeding appears to be a good proxy for natural biting, strengthen the reliability 
of these existing models. 
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 Our current nested sub-study was limited by the fact that it was only conducted at a 
single timepoint at day 7 post-treatment. Future studies could examine differences between 
direct and membrane feeding at lower and higher concentrations, at earlier or later time 
points post-treatment, and using both ivermectin and other endectocides such as 
moxidectin, eprinomectin, fluralaner and afoxolaner [20-22] which have different 
pharmacokinetics. Furthermore, the trial only assessed mosquito mortality and did not 
assess any possible sublethal effects, such as on sporogony and oviposition (laying of eggs), 
which could be relevant especially at low concentrations and could be investigated in 
further studies. It is unknown if our results can be extrapolated to the pediatric population 
because ivermectin pharmacokinetics, including the capillary-venous ratio, in children are 
not yet known. 
 In conclusion, both direct skin feeding and membrane feeding on day 7 resulted in 
similar mosquito mortality of An. gambiae after ivermectin treatment across a wide range of 
drug concentrations and this was similar by sex and BMI, suggesting that the mosquitocidal 
effects observed with membrane feeding in the main trial depict those of natural biting. 
Membrane feeding, which is more patient-friendly and allows a larger number of mosquito 
observations, likely accurately reflects ivermectin’s mosquitocidal effects.
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Table 1: Characteristics of subjects that participated in both direct skin and membrane feeding 
 Ivermectin 600 mcg/kg 
per day for 3 days 
(n=22) 
Ivermectin 300 mcg/kg  
per day for 3 days 
(n=24) 
Placebo 
(n=23) 
Age, years 27.3 (7.4) 25.5 (7.5) 26.0 (5.0) 
Sex    
   Male 13 (59%) 16 (67%) 14 (61%) 
   Female 9 (41%) 8 (33%) 9 (39%) 
Body mass index, kg/m2 22.9 (3.4) 21.5 (3.0) 21.6 (2.6) 
Data are n (%), or mean (SD). Baseline characteristics of subjects that participated in both direct 
skin and membrane feeding (n=69) were similar to those of the other trial participants that did 
not (n=72) [6]. 
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Table 2: Proportion of fully fed mosquitoes after direct skin feeding and membrane feeding 
Feeding 
Method 
Human Subjects; Mosquitoes fully fed (%)* Risk ratio (95% CI), p-value 
IVM-3x600 IVM-3x300 Placebo IVM-3x600 vs Placebo IVM-3x300 vs Placebo IVM-3x600 vs IVM-3x300 
Direct Skin 22 938/1096 (85.6) 24 1015/1199 (84.7) 23 988/1151 (85.8) 1.00 (0.89, 1.11), 0.95 0.99 (0.88, 1.10), 0.80 1.01 (0.91, 1.12), 0.84 
Membrane 22 2584/3300 (78.3) 24 2533/3613 (70.1) 23 2263/3455 (65.5) 1.20 (0.99, 1.45), 0.07 1.07 (0.88, 1.30), 0.51 1.12 (0.94, 1.33), 0.20 
Abbreviations: IVM-3x600=ivermectin 600 mcg/kg/day for 3 days, IVM-3x300=ivermectin 300 mcg/kg/day for 3 days. 
* The number of mosquitoes fully fed out of the number of mosquitoes offered a blood meal. 
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Table 3: Mosquito mortality following direct skin feeding and membrane feeding 
Treatment 
Group 
Human 
Subjects 
Mosquito mortality on day 14 (%) Risk or Hazard ratio (95% CI), p-value 
Direct Skin Feeding Membrane Feeding* Model Direct vs Membrane 
IVM-3x600 22 890/938 (94.9) 
1677/1729 (97.0) GEE RR 0.98 (0.90, 1.06), 0.55 
2514/2584 (97.3) Cox HR 0.93 (0.86, 1.00), 0.052 
IVM-3x300 24 938/1015 (92.4) 
1573/1703 (92.4) GEE RR 1.01 (0.98, 1.03), 0.69 
2330/2533 (92.0) Cox HR 1.01 (0.93, 1.09), 0.80 
Placebo 23 503/988 (50.9) 
706/1493 (47.3) GEE RR 1.07 (0.88, 1.29), 0.51 
999/2263 (44.1) Cox HR 1.03 (0.92, 1.15), 0.58 
Abbreviations: IVM-3x600=ivermectin 600 mcg/kg/day for 3 days, IVM-3x300=ivermectin 300 mcg/kg/day 
for 3 days. HR=hazard ratio, RR=risk ratio. 
* GEE models used 2 cups of mosquitoes followed for 14 days; Cox models used the same 2 cups, plus 1 cup 
followed for 10 days which were then euthanized for oocyst PCR. 
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Figure 1: Trial flowchart 
 
 
Figure 2: Mosquito mortality stratified by treatment arm and feeding method 
 
Mosquito mortality stratified by feeding method (direct skin feeding: dashed lines; membrane 
feeding: solid lines) and treatment arm (ivermectin 600 mcg/kg/day: green lines, ivermectin 300 
mcg/kg/day: red lines, and placebo: blue lines), following feeding on day 7 post-treatment. Hazard 
ratios (HR, 95% confidence interval, p-value) of mortality during 14 days post-feeding, comparing 
direct versus membrane feeding for each treatment arm, were adjusted for mosquito clusters. 
Figure 3: Capillary versus venous ratios of ivermectin plasma concentration during 2-7 
days post-treatment 
 
Open circles represent capillary versus venous ratios of observed ivermectin plasma concentrations 
for each sample (n=177) taken from patients in the main trial contributing capillary samples (n=61) 
during 2-7 days post-treatment (maximum 4 samples/patient). Ball-whiskers indicate median±IQR 
per sampling day. Horizonal line indicates median ratio of 1.33 (p5-p95: 0.98-1.63) based on the 
trial’s simultaneous PK-PD population model [10]. Adapted from: Smit MR (2018) Clin Pharmacol 
Ther [10]. 
Figure 4: Direct skin feeding versus membrane feeding ratios of mosquito mortality rates 
by ivermectin concentration and capillary-venous ratio at the time of feeding 
a) b) 
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c) d) 
  
Circles represent observed 14-day mosquito mortality rate ratios of direct versus membrane feeding 
performed at day 7 post-treatment for each patient that received ivermectin and consented to 
direct skin feeding (n=46), plotted against their day 7 (a) predicted ivermectin capillary plasma 
concentration and (b) predicted capillary versus venous ratio using the trial’s simultaneous PK-PD 
population model [10]. (c) and (d) as per (b), but now stratified by sex and body-mass-index, 
respectively. Lines indicate the linear fits.  
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741 adults with malaria assessed for eligibility
600 excluded
540 did not meet eligibility criteria
60 declined to participate
47 assigned to ivermectin
600 mcg/kg/day for 3 days
48 assigned to ivermectin
300 mcg/kg/day for 3 days
46 assigned to placebo
43 received all 3 allocated doses 47 received all 3 allocated doses 46 received all 3 allocated doses
43 attended day 7 visit 41 attended day 7 visit 44 attended day 7 visit
22 participated in both direct skin 
and membrane feeding
24 participated in both direct skin 
and membrane feeding
23 participated in both direct skin 
and membrane feeding
141 randomized
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